Clinical trials
Hormone Receptor Positive Malignant Neoplasm of Breast clinical trials
Below are recruiting hormone receptor positive malignant neoplasm of breast clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05981014RecruitingPhase 1/Phase 2
Immune cells from lymph nodes for HER2-negative breast cancer
This trial tests whether taking immune cells from your lymph nodes and giving them back to you can help shrink breast cancer that has not responded fully to initial chemotherapy. It is for women with HER2-negative breast cancer who have had stable disease after two cycles of a standard chemotherapy combination.
Guangzhou, GuangdongAges 18–70 - NCT05981001RecruitingPhase 1/Phase 2
Experimental cell therapy for advanced HER2-negative breast cancer
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
Guangzhou, GuangdongAges 18–70 - NCT06121557RecruitingPhase 1
Immune cells from lymph nodes for advanced HER2-negative breast cancer
This trial tests a treatment using your own immune cells taken from lymph nodes near the tumor. The cells are grown in a lab and given back to you to fight cancer, along with another drug chosen by your doctor.
Guangzhou, GuangdongAges 18–70 - NCT06121570RecruitingPhase 1
Study of immune cells from lymph nodes for HER2-negative breast cancer
This trial tests whether using a patient's own immune cells from lymph nodes near the tumor, given as a treatment before surgery, can help shrink HER2-negative breast cancer. It is for people whose cancer has not responded fully to two cycles of initial chemotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06974604RecruitingPhase 2
Mouthwash to prevent mouth sores from Datopotamab deruxtecan
This trial tests if a dexamethasone mouthwash can prevent painful mouth sores (stomatitis) caused by the cancer drug Datopotamab deruxtecan (Dato-DXd). It's for people with certain types of advanced lung or breast cancer who have already tried other treatments.
Providence, Rhode IslandAges 18 years+ - NCT07060807RecruitingPhase 3
Study of Patritumab Deruxtecan for Advanced HR+/HER2- Breast Cancer
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
Daphne, AlabamaAges 18 years+ - NCT05277935Recruiting
Wearable activity tracking for hormone-positive metastatic breast cancer
This study tests whether using a wearable watch and smartphone app to track activity and fitness can help monitor health in people with hormone receptor–positive, HER2-negative metastatic breast cancer while they take standard hormone therapy plus palbociclib. It mainly requires that you are already on these medicines for at least three months and can use the devices reliably.
Rio de JaneiroAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT06272799Recruiting
T-DM1 after incomplete response to initial breast cancer therapy
This trial is for people with HER2-positive breast cancer who still had cancer after initial chemotherapy. It tests the safety and effectiveness of a drug called T-DM1 (Kadcyla) given after surgery to reduce the chance of the cancer coming back.
Rome, RomeAges Any age - NCT06979596RecruitingPhase 2
A study of MK-5684 for certain solid tumors
This trial tests an investigational drug called MK-5684 for people with specific types of breast, ovarian, or endometrial cancer. It aims to see if this treatment can help shrink or control the cancer when standard treatments have stopped working or are no longer effective.
Anchorage, AlaskaAges 18 years+ - NCT06385990RecruitingPhase 2
Utidelone plus Capecitabine for residual triple-negative breast cancer
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
Changsha, HunanAges 18–70
Hear when a new Hormone Receptor Positive Malignant Neoplasm of Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hormone receptor positive malignant neoplasm of breast?
- Yes. Clin2 currently lists 35 recruiting hormone receptor positive malignant neoplasm of breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hormone receptor positive malignant neoplasm of breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hormone receptor positive malignant neoplasm of breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hormone-receptor-positive Breast Cancer
- Hormone Receptor Positive Breast Carcinoma
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Metastatic Hormone Receptor-Positive Breast Carcinoma
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Estrogen-receptor-positive Breast Cancer
- Hormone Receptor Positive Tumor
- Malignant Neoplasm of Breast
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.